daclizumab trade name zinbryta therapeutic humanized monoclonal antibody used treatment adults relapsing forms multiple sclerosis ms daclizumab works binding alpha subunit receptor tcells march voluntarily withdrawn market biogen abbvie reports autoimmune encephalitis daclizumab used treat adults relapsing forms multiple administered clinical trials decreases annualized relapse rate reported well reduction proportion patients relapsed reduction number new cochrane systematic review concluded insufficient evidence determine efficacy daclizumab relative placebo people relapsingremitting ms prior discontinued need investigate longer lengths treatment daclizumab approved used prevent acute rejection kidney transplant along cyclosporine indication side effects frequency least included sleeplessness tremor headache arterial hypertension dyspnoea gastrointestinal side effects oedema rare cases drug could cause severe us daclizumab approved contraindicated people liver impairment including significantly elevated liver enzymes alt ast autoimmune european medicines agency ema originally approved drug without contraindications apart known required biogen implement hepatic risk management guide july ema issued provisional contraindication patients preexisting liver disease liver marketing authorisation withdrawn eu march ema review concluded medicine poses risk serious potentially fatal immune reactions affecting brain liver clinical trials ms treatmentrelated deaths increased risk cancer side effects occurred frequently daclizumab versus interferon included infections versus skin rashes versus liver complications approximately versus antibody daclizumab expected low potential pharmacokinetic interactions daclizumab blocks receptors containing alpha subunit include highaffinity receptors mediumaffinity receptors hand consist two beta subunits affected daclizumab exact mechanism unknown net effect reduction tcell responses expansion natural killer subcutaneous injection single dose daclizumab bioavailability reaches highest blood plasma levels days given every four weeks steady state concentrations found fourth dose expected daclizumab like antibodies degraded proteases peptides finally amino acids interact cytochrome liver biological halflife days patients developed antibodies daclizumab eliminated daclizumab created scientists pdl biopharma called protein design labs time humanizing mouse mab called antitac targets receptor Î± chain blocks interaction receptor prevents activation antitac discovered thomas waldmann md chief metabolism branch national cancer institute team conducted animal studies small clinical trial antitac people tcell leukemia promising results people quickly developed antibodies rejecting mouse protein waldman colleagues approached protein design labs humanize pdl nih scientists approached roche leader transplant medicine development get drug developed approved pdl didnt resources actually bring product march drug removed market worldwide december daclizumab approved fda use preventing acute rejection kidney transplants combination ciclosporin corticosteroids first humanized antibody approved anywhere launch average wholesale price drug estimated five doses estimated annual sales would million million within five years launch thought drugs use would expanded use organ approved europe pdl began clinical trials daclizumab september drug shown promise phase ii trial pdl roche agreed expand relationship include codevelopment daclizumab asthma respiratory august pdl biogen idec agreed collaborate develop daclizumab indications outside fields organ rejection respiratory november roche pdl agreed try develop formulation daclizumab would useful subcutaneous injection longterm maintenance organ next year roche pdl announced collaboration indications announced discontinuing zenapax worldwide view available alternative treatments diminishing market demand due safety pdl spun active development programs company called facet biotech development daclizumab multiple sclerosis partnership biogen included biogen attempted hostile buy facet facet rejected offer purchased abbvie million cash next may fda approved daclizumab treatment relapsing multiple sclerosis adults trade name zinbryta requirements postmarketing studies submit formal risk evaluation mitigation daclizumab studied small clinical trial people birdshot immune activation dostarlimab ibalizumab httpsenwikipediaorgwikidaclizumab